All News

SLE,malar,black

Does Dendritic Cell Targeted Therapy Work in SLE?

d Jack Cush, MD

A phase 2 trial using litifilimab, a humanized monoclonal antibody binding to blood dendritic cell antigen 2 (BDCA2), demonstrated clinical efficacy in adults with systemic lupus erythematosus (SLE).

Read Article
IPF.lancet.jpg

Pirfenidone Potential in RA-Related Lung Disease

d MedPage Today

Rheumatoid arthritis patients with existing interstitial lung disease (ILD) had less decline in lung function when receiving the antifibrotic agent pirfenidone (Esbriet) relative to placebo in a randomized trial, researchers reported here and in a simultaneous journal publication.

Read Article
Rheumatoid,RA,nodules,damage

Global Trends Informing the Future of Rheumatoid Arthritis

d Jack Cush, MD

Finkh et al report on the prevalence and interesting trends in rheumatoid arthritis (RA), including its higher prevalence in industrialized countries and declining disease severity over time. 

Read Article
heart,cv,meds, events, CVD

Study Reassures on HCQ Heart Risks in Rheumatoid Arthritis

d MedPage Today

Among U.S. veterans receiving hydroxychloroquine (HCQ) as long-term therapy for rheumatoid arthritis, development of long QT syndrome was rare and not markedly more common compared with similar patients treated with other agents, researchers said.

Read Article
DPGN, lupus, nephritis, GN, glomerulonephritis, biopsy, kidney

Voclosporin Efficacy and Safety in Lupus Nephritis

d Jack Cush, MD

An integrated analysis of two pivotal trials of voclosporin, a calcineurin inhibitor, in lupus nephritis patients saw significant improvement in complete renal responses (CRR) at one year.

Read Article
Spanish SpA Registry (REGISPONSER) - 18.3% had psoriasis; w/ 3/4 of these (76%) having PSO before MSK Sxs. Pts w/ PSO before MSK Sxs had shorter dz duration, lower BMI, Less B27 & anterior uveitis, more dactylitis and ^risk PsA dx (78% vs 56%) https://t.co/b9Qa6fL9eM https://t.co/6nRu0iuP1a

Links:

Dr. John Cush RheumNow ( View Tweet)
Rheums! Have a Rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/1aSrRsLkel https://t.co/gmh155ty6w

Links:

Dr. John Cush RheumNow ( View Tweet)
Systematic review of Telemedicine in Rheumatology - 36 reports: 27 observational studies, 7 RCTs , 2 controlled trials - most on general rheum. Most show TM as good as usual / in-person care (Dzactivity, pt satisfaction, costs, & feasibility). TM Works https://t.co/04QW8UiB8j https://t.co/846sqKbnX1

Links:

Dr. John Cush RheumNow ( View Tweet)
STARTER study looked at US in 256 RA pts completed the study & were Rx w/ biologics csDMARDS or combination DMARDs. Pts w/ US grey scal or power doppler tenosynovitis better controlled in combination DMARDs than csDMARDs alone (p:0.025) https://t.co/MXLVoIxzmw https://t.co/8N5aV3vAA0

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of 130 patients with ITP (w/ 10 later Dx SLE (30 mos F/U). Risk factors for ITP developing SLE included young age (< 40yrs; OR 6.3), organ bleeding (OR 13.7), and ANA (≥ 1:160; OR 6.6) https://t.co/XSJdio2rR1 https://t.co/oCyFjJnxTX

Links:

Dr. John Cush RheumNow ( View Tweet)
StillsNow Podcast August 2022 - Genetic Testing for Autoinflammatory Diseases Featuring a discussion with Dr. Susan Shenoi from Seattle Childrens Hospital https://t.co/W9e6r83R6B https://t.co/rVvDurZz2g

Links:

Dr. John Cush RheumNow ( View Tweet)
New download! Seven Ways to Diagnose Arthritis - Labs https://t.co/mNkLgTj3DW https://t.co/0UTe7ny5Fo

Links:

Dr. John Cush RheumNow ( View Tweet)
Voclosporin Efficacy and Safety in Lupus Nephritis An integrated analysis of two pivotal trials of voclosporin, a calcineurin inhibitor, in lupus nephritis patients saw significant improvement in complete renal responses (CRR) at one year. https://t.co/LSjmRB2Zr3 https://t.co/z9MoJ0uRzz

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of 100 Korean systemic sclerosis pts, shows that while many had SSc finger involvement, fingerprints is SSc pts did not change significantly, but may be inadequate/ difficulr with finger deformity, acroosteolysis or digital ulcers https://t.co/JjTIiaLYZv https://t.co/kcFUobVnvi

Links:

Dr. John Cush RheumNow ( View Tweet)
ACR RISE Registry, 9,560 gout pts- ONLY 56% of patients had > = one Serum Urate recorded during the year; amongst those w/ 1 SU recorded, 74% achieved the SU target. ONLY HALF? GETTING SUAs? Are we not Rheums? https://t.co/OfKRWtyjBT https://t.co/8kjwEVZwB3

Links:

Dr. John Cush RheumNow ( View Tweet)
Multicentre matched control study looked at primary Sjogrens that developed lymphoma or NOT. Parotid swelling (PSW) is an early major predictor of non-Hodgkin lymphoma in pSS; esp if present before or dx, & w/ a longer duration of PSW https://t.co/QokXF6klEv https://t.co/YqFgAqt4ku

Links:

Dr. John Cush RheumNow ( View Tweet)
Hypertension Associated with RA and OA Analysis of NHANES data suggests that both rheumatoid arthritis (RA) and osteoarthritis (OA) are strongly associated with hypertension (HTN). https://t.co/HUWUvOKcMw https://t.co/6GkeEWQP40

Links:

Dr. John Cush RheumNow ( View Tweet)
Genetic Testing for Autoinflammatory Disease Not all patients with periodic fevers fit neatly into diagnostic categories. Some can be diagnosed as Still’s disease (based on criteria) while others can be classified as AID and some may be unclassifiable. https://t.co/E5qZS1JyAY https://t.co/PYgUbiduPF

Links:

Dr. John Cush RheumNow ( View Tweet)
Nintedinib has been studied in 39 children (6–17 yrs) with fibrosing ILD demonstrating pharmacokinetics (wt based dosing) and safety. Adjusted mean changes in FVC % at week 24 were 0.3 with nintedanib and −0.9 with placebo https://t.co/yQ7OREzpTR https://t.co/iylG9BZiz4

Links:

Dr. John Cush RheumNow ( View Tweet)
B12 or Placebo effect? Open label study of B12 (1000mcg/d) in 29 fibromyalgia pts showed after 50d, significant reductions in FM Impact Quest. (FIQR; 49.8 to 40.00; p< 0.01), Function, Sxs, anxiety scores all signif improved. https://t.co/MtJWy5xlz9 https://t.co/kzvA1wd3zb

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×